A urinary peptidomic biological age clock built from capillary electrophoresis-mass spectrometry data across 17,000+ participants achieved age prediction within 4.91–5.47 years of chronological age and, after kidney-function correction, demonstrated that each standard-deviation increment in age acceleration raised all-cause mortality risk by 48% (HR 1.48, 95% CI 1.35–1.63). The same metric independently predicted incident coronary artery disease (+44%), heart failure (+27%), and chronic kidney disease progression (+35%) over a median 3.95-year follow-up of 7,469 participants.
This work is notable for directly confronting a blind spot that undermines most urinary biomarker research: kidney function confounds peptide concentrations. By conditioning the clock on eGFR and albumin-to-creatinine ratio via a dedicated calibration step, the authors produced a corrected score with broad applicability — though the clock lost predictive signal in severe kidney impairment (eGFR 15–29) and macroalbuminuria, limiting use in the sickest patients. Compared to DNA-methylation clocks, urine collection is non-invasive and scalable, and the authors explicitly design this clock for intervention responsiveness — a key gap in the aging-clock field where most tools describe but cannot track change. Effect sizes are clinically meaningful and consistent across sexes. Limitations include retrospective design, relatively short follow-up, and a clinically enriched (not purely population) cohort. As a preprint not yet peer-reviewed, these findings require independent replication and scrutiny before clinical adoption. Incremental rather than paradigm-shifting, but methodologically rigorous.
